Prevalence of Vitamin D Deficiency in Patients with Stage 3/4 Chronic Kidney Disease and Its Relation to Secondary Hyperparathyroidism

Objective: The extent of bone mineral disorders in predialysis patients is not well defined. This study aimed to detect the prevalence of both 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) deficiency in patients with stage 3-4 chronic kidney disease (CKD) and its relation to secondary hyperparathyroidism.

Materials and Methods: In this study, 113 patients with stage 3-4 CKD admitted to our outpatient clinic were included. Clinical, demographic, and lifestyle characteristics of patients were recorded. Patients’ serum creatinine, calcium, phosphorus, 25(OH)D, 1,25(OH)2D, and parathormone (PTH) levels were measured.

Results: We found that 85 patients (75.2%) had stage 3 CKD, and 28 patients (24.8%) had stage 4 CKD. A low 25(OH)D level was detected in 89.4% of the patients (stage 3 CKD 89.4%, stage 4 CKD 89.3%). The PTH level was higher in patients with low 25(OH)D level with a borderline statistical significance (p=0.057). The number of patients with 1,25(OH)2D level lower than 54.53 pg/ml was 28 (24.77%), which was accepted as a cut-off value. The mean PTH level was significantly higher in the group with lower 1,25(OH)2D (P=0.048). The prevalence of secondary hyperparathyroidism was found as 57.5%.

Conclusion: We found a high prevalence of bone mineral disorders among patients with stage 3–4 CKD. These results point out the importance of timely diagnosis and appropriate treatment.

Cite this article as: Pala AS, Kaya E, Alagöz S, Trabulus S, Bolayırlı M, Altıparmak MR, Seyahi N. Prevalence of Vitamin D Deficiency in Patients with Stage 3/4 Chronic Kidney Disease and Its Relation to Secondary Hyperparathyroidism. Turk J Nephrol 2019; 28(2): 132-7.